- BioCryst Pharmaceuticals (NASDAQ:BCRX) announces that the European Medicines Agency (EMA) has approved ALPIVAB (peramivir), a single intravenous (IV) infusion for the treatment of uncomplicated influenza in patients at least two years old.
- The company says the approval triggers a $5M milestone payment from licensee Seqirus, although it adds that the two companies are currently involved in a dispute over certain claims in their contract.
BioCryst's IV flu drug Alpivab OK'd in Europe
Recommended For You
About BCRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BCRX | - | - |
BioCryst Pharmaceuticals, Inc. |